Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
Cidara Therapeutics Announces Key Additions to its Board of Directors
Read Article
News
2021
2020
Archive
August 10, 2009
IKARIA TO IN-LICENSE WORLDWIDE RIGHTS TO INVESTIGATIONAL PORTFOLIO FROM FIBREX MEDICAL
July 6, 2009
IKARIA TO IN-LICENSE BIOLINERX’S BL-1040
June 12, 2009
FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN®
June 1, 2009
ENTREMED PRESENTS RESULTS OF ENMD-2076 PHASE 1 STUDY IN ADVANCED CANCER PATIENTS
May 16, 2009
ACHAOGEN DATA SHOW RAPID RISE IN RATES OF RESISTANCE TO CURRENT ANTIBIOTICS; ILLUSTRATE GLOBAL NEED FOR NEW, WELL-TOLERATED AGENTS TO ADDRESS VARIED MECHANISMS OF RESISTANCE
May 13, 2009
SYNOSIA THERAPEUTICS BEGINS PHASE I TRIAL OF A NEW GENERATION TREATMENT FOR COGNITIVE IMPAIRMENT
May 1, 2009
PULMATRIX ANNOUNCES PH 1B/2A CLINICAL TRIAL OF NOVEL ICALM THERAPY FOR FLU
March 10, 2009
SYNOSIA ANNOUNCES SECOND AGREEMENT WITH ROCHE
March 9, 2009
IGENICA APPOINTS DR. MIKE ROTHE AS CEO AFTER CLOSING SERIES A FINANCING
March 3, 2009
ACHAOGEN SIGNS $26.6 MILLION CONTRACT WITH NIAID FOR DEVELOPMENT OF NEW THERAPY TO TREAT RESISTANT STRAINS OF NIAID CATEGORY A AND B PRIORITY PATHOGENS
« Previous Page
1
…
70
71
72
73
Next Page »
